Last updated: May 27, 2026
Cetrorelix Acetate Suppliers: Who Makes API and Finished Drug, and What Supply Risks Matter
Cetrorelix acetate supply is split between (1) API manufacturers that produce the peptide active ingredient under GMP and (2) finished-dose manufacturers that hold marketing authorization and produce the injectable product used by healthcare systems. For “CETRORELIX ACETATE” procurement planning, the practical supplier set is determined by the drug’s regulatory listing (originator/MAH), which often constrains the approved supply chain and can shift during shortages via contract manufacture.
Which companies supply cetrorelix acetate API?
Cetrorelix acetate is a synthetic gonadotropin-releasing hormone (GnRH) antagonist peptide (trade name Cetrotide in many markets). API supply is typically provided by specialized peptide and active ingredient GMP producers with peptide synthesis and purification capability, including salt formation to cetrorelix acetate.
API supplier set (typical structure in the market)
- Peptide API manufacturers: produce cetrorelix (free base or corresponding precursor) and convert to the acetate salt, with analytical release for peptide identity, impurities, and residual solvents/reagents under GMP.
- Contract API producers for the originator/MAH: may manufacture API for the marketing authorization holder (MAH) and support multiple finished-dose lines through contracted sterile fill-finish partners.
- Distributor-procured API: in some procurement models, the finished-dose manufacturer sources API from approved GMP suppliers and does not publicize the upstream API vendor in marketing materials.
What procurement teams should confirm for API qualification
- GMP certificate coverage for peptide manufacture and salt formation
- Impurity profile consistency and change-control history
- Regulatory status of the API (whether it is directly listed in the dossier for specific jurisdictions)
- Supply capacity and lead time for sterile-finish-adjacent timelines (API to bulk DP to vial/labeling)
Who supplies Cetrotide (cetrorelix acetate) finished product?
Finished cetrorelix acetate injection is typically supplied by the MAH or by contract manufacturing organizations (CMOs) under the MAH’s quality system. Finished-dose supply can move between sterile fill-finish partners when volumes surge or during regulatory inspections.
Finished product supplier mapping (how to structure a supplier list)
- MAH (marketing authorization holder): the company responsible for product quality and release in each country/region.
- Manufacturing sites (sterile manufacturing and packaging): often different sites for bulk drug substance processing vs final sterile fill-finish.
- Regional distributors: procurement can route through local wholesalers even when the global manufacturer is the same.
What suppliers provide cetrorelix acetate in the US market (Orange Book pathway)?
In the US, cetrorelix acetate’s status determines whether suppliers include multiple FDA-approved manufacturers or only the originator’s marketed product. The most actionable procurement view is:
- FDA-listed drug product manufacturers (from FDA labeling and submission history)
- NDC-level supply and whether any ANDA/therapeutic equivalent exists for the same dosage form
For accurate “supplier” identification at procurement level in the US, the supplier list must be anchored to:
- the FDA Orange Book listing for the product,
- the NDC product labels, and
- the manufacturing and testing site addresses listed on label sections and FDA records.
Which suppliers are active in the EU/UK market for cetrorelix acetate?
EU and UK sourcing is commonly managed through:
- the EMA/National competent authority marketing authorization holder, and
- local distributors operating under the MAH’s supply agreement.
For procurement, “supplier” usually means:
- the MAH and its contracted sterile fill-finish sites, and
- wholesale distributors that can reliably supply the exact presentation (vials, unit strength, and packaging format).
How does shortage history affect cetrorelix acetate supplier availability?
Peptide injectable products can face supply instability from:
- peptide synthesis batch failures,
- raw material peptide intermediates and reagents,
- sterile manufacturing constraints (fill-finish capacity),
- quality system deviations leading to temporary release pauses.
When shortages occur, procurement teams typically see:
- substitution between equivalent NDCs/presentations (same active, different packaging),
- increased lead times,
- increased reliance on alternate contract sterile sites.
A supplier due diligence package for cetrorelix acetate should include:
- minimum batch submission history over the last 12 to 24 months,
- sterile fill-finish risk assessment,
- and change-control history for both API synthesis and DP sterile steps.
What qualification documents do purchasers require from cetrorelix acetate suppliers?
For peptide injectables, supplier qualification should cover both chemistry and sterile process controls.
Core supplier document set
- GMP certificate(s) for relevant sites
- Quality Agreement between supplier and purchaser (or MAH/contract chain)
- CoA for recent lots
- Drug Master File (DMF) access terms if API is controlled
- CMC change notification commitments for impurity profile or manufacturing changes
- Stability summary and shipping/handling conditions
Supplier comparisons: API vs finished product roles
A procurement shortlist should separate suppliers by function because responsibilities differ:
| Supplier type |
Typical role |
What they supply |
Main qualification focus |
| API manufacturer |
Peptide synthesis and salt formation |
Cetrorelix acetate bulk API |
GMP peptide process controls, impurity profile, salt spec |
| DP (sterile) manufacturer |
Sterile fill-finish and packaging |
Vial drug product |
Aseptic processing controls, container closure integrity |
| MAH/brand holder |
Regulatory responsibility and release |
Marketed product under label |
Batch release oversight, quality system, supply chain governance |
| Wholesaler/distributor |
Commercial distribution |
Market-ready inventory |
Temperature control, chain-of-custody, lead-time reliability |
What manufacturing/IP barriers limit alternate suppliers for cetrorelix acetate?
Barriers tend to be less about basic chemistry and more about:
- peptide manufacturing know-how and process robustness,
- validated sterile fill-finish process parameters,
- impurity acceptance criteria tied to reference product,
- and regulatory dossier dependence (where the supplier’s CMC package must match the registered specs).
Even if multiple GMP peptide sites can synthesize cetrorelix, only those with dossier-ready capability and sterile production readiness can consistently supply.
Key Takeaways
- Cetrorelix acetate supply is constrained by peptide API GMP capability plus sterile fill-finish capacity and MAH quality system governance.
- Procurement “supplier” lists should be organized by API manufacturer, sterile DP manufacturer, MAH, and regional distributors, because each has different documentation and responsibility.
- Shortage risk is tied to peptide synthesis batch yield and sterile manufacturing release continuity, not just API availability.
- Supplier qualification for cetrorelix acetate should prioritize GMP coverage, impurity profile control, and sterile process qualification records.
FAQs
- How do I identify cetrorelix acetate suppliers by NDC and manufacturing site?
- What GMP requirements apply to peptide API manufacturing for cetrorelix acetate?
- Which documents should be requested to qualify a new cetrorelix acetate DP supplier?
- How should procurement teams handle cetrorelix acetate shortages and substitute presentations?
- What factors most impact cetrorelix acetate supply continuity in sterile fill-finish?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (US). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. Drug Labeling and related submission information (for manufacturing site and product details). https://www.accessdata.fda.gov/scripts/cder/daf/
- EMA. European public assessment reports (EPAR) and product information for cetrorelix acetate products. https://www.ema.europa.eu/
